{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:22:13Z","timestamp":1788398533496,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0310113"],"award-info":[{"award-number":["JP21fk0310113"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K07522"],"award-info":[{"award-number":["JP21K07522"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>While certain human hepatitis B virus-targeting nucleoside analogs (NAs) serve as crucial anti-HBV drugs, HBV yet remains to be a major global health threat. <jats:italic>E<\/jats:italic>-CFCP is a 4\u2032-modified and fluoromethylenated NA that exhibits potent antiviral activity against both wild-type and drug-resistant HBVs but less potent against human immunodeficiency virus type-1 (HIV-1). Here, we show that HIV-1 with HBV-associated amino acid substitutions introduced into the RT\u2019s dNTP-binding site (N-site) is highly susceptible to <jats:italic>E<\/jats:italic>-CFCP. We determined the X-ray structures of HBV-associated HIV-1 RT mutants complexed with DNA:<jats:italic>E<\/jats:italic>-CFCP-triphosphate (<jats:italic>E<\/jats:italic>-CFCP-TP). The structures revealed that exocyclic fluoromethylene pushes the Met184 sidechain backward, and the resultant enlarged hydrophobic pocket accommodates both the fluoromethylene and 4\u2032-cyano moiety of <jats:italic>E<\/jats:italic>-CFCP. Structural comparison with the DNA:dGTP\/entecavir-triphosphate complex also indicated that the cyclopentene moiety of the bound <jats:italic>E<\/jats:italic>-CFCP-TP is slightly skewed and deviated. This positioning partly corresponds to that of the bound dNTP observed in the HIV-1 RT mutant with drug-resistant mutations F160M\/M184V, resulting in the attenuation of the structural effects of F160M\/M184V substitutions. These results expand our knowledge of the interactions between NAs and the RT N-site and should help further design antiviral NAs against both HIV-1 and HBV.<\/jats:p>","DOI":"10.1038\/s41598-024-66505-z","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T17:02:49Z","timestamp":1720458169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations"],"prefix":"10.1038","volume":"14","author":[{"given":"Yoshiaki","family":"Yasutake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kumamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"66505_CR1","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"MF Yuen","year":"2018","unstructured":"Yuen, M. F. et al. Hepatitis B virus infection. Nat. Rev. Dis. Primers 4, 18035. https:\/\/doi.org\/10.1038\/nrdp.2018.35 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"66505_CR2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","volume":"7","author":"CJ Alberts","year":"2022","unstructured":"Alberts, C. J. et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: A systematic review. Lancet Gastroenterol. Hepatol. 7, 724\u2013735. https:\/\/doi.org\/10.1016\/S2468-1253(22)00050-4 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"66505_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"YC Hsu","year":"2023","unstructured":"Hsu, Y. C., Huang, D. Q. & Nguyen, M. H. Global burden of hepatitis B virus: Current status, missed opportunities and a call for action. Nat. Rev. Gastroenterol. Hepatol. 20, 524\u2013537. https:\/\/doi.org\/10.1038\/s41575-023-00760-9 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"66505_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jhep.2015.03.020","volume":"63","author":"S Hayashi","year":"2015","unstructured":"Hayashi, S. et al. Characterization of novel entecavir resistance mutations. J. Hepatol. 63, 546\u2013553. https:\/\/doi.org\/10.1016\/j.jhep.2015.03.020 (2015).","journal-title":"J. Hepatol."},{"key":"66505_CR5","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1128\/aac.46.8.2525-2532.2002","volume":"46","author":"S Levine","year":"2002","unstructured":"Levine, S. et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 46, 2525\u20132532. https:\/\/doi.org\/10.1128\/aac.46.8.2525-2532.2002 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"66505_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cld.2019.04.006","volume":"23","author":"U Lopatin","year":"2019","unstructured":"Lopatin, U. Drugs in the pipeline for HBV. Clin. Liver Dis. 23, 535\u2013555. https:\/\/doi.org\/10.1016\/j.cld.2019.04.006 (2019).","journal-title":"Clin. Liver Dis."},{"key":"66505_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","volume":"119","author":"E De Clercq","year":"2016","unstructured":"De Clercq, E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem. Pharmacol. 119, 1\u20137. https:\/\/doi.org\/10.1016\/j.bcp.2016.04.015 (2016).","journal-title":"Biochem. Pharmacol."},{"key":"66505_CR8","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40265-017-0754-9","volume":"77","author":"LJ Scott","year":"2016","unstructured":"Scott, L. J. & Chan, H. L. Y. Tenofovir alafenamide: A review in chronic hepatitis B. Drugs 77, 1017\u20131028. https:\/\/doi.org\/10.1007\/s40265-017-0754-9 (2016).","journal-title":"Drugs"},{"key":"66505_CR9","first-page":"59","volume":"18","author":"JL Casado","year":"2016","unstructured":"Casado, J. L. Renal and bone toxicity with the use of tenofovir: Understanding at the end. AIDS Rev. 18, 59\u201368 (2016).","journal-title":"AIDS Rev."},{"key":"66505_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.jhep.2020.12.006","volume":"74","author":"N Higashi-Kuwata","year":"2021","unstructured":"Higashi-Kuwata, N. et al. Identification of a novel long-acting 4\u02b9-modified nucleoside reverse transcriptase inhibitor against HBV. J. Hepatol. 74, 1075\u20131086. https:\/\/doi.org\/10.1016\/j.jhep.2020.12.006 (2021).","journal-title":"J. Hepatol."},{"key":"66505_CR11","doi-asserted-by":"publisher","first-page":"199094","DOI":"10.1016\/j.virusres.2023.199094","volume":"329","author":"Y Takamatsu","year":"2023","unstructured":"Takamatsu, Y. et al. A novel anti-HBV agent, E-CFCP, restores hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes. Virus Res. 329, 199094. https:\/\/doi.org\/10.1016\/j.virusres.2023.199094 (2023).","journal-title":"Virus Res."},{"key":"66505_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0092-8674(82)90157-x","volume":"29","author":"J Summers","year":"1982","unstructured":"Summers, J. & Mason, W. S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29, 403\u2013415. https:\/\/doi.org\/10.1016\/0092-8674(82)90157-x (1982).","journal-title":"Cell"},{"key":"66505_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/jvi.68.1.6-13.1994","volume":"68","author":"F Zoulim","year":"1994","unstructured":"Zoulim, F. & Seeger, C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J. Virol. 68, 6\u201313. https:\/\/doi.org\/10.1128\/jvi.68.1.6-13.1994 (1994).","journal-title":"J. Virol."},{"key":"66505_CR14","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1128\/jvi.02575-13","volume":"88","author":"J V\u00f6r\u00f6s","year":"2013","unstructured":"V\u00f6r\u00f6s, J. et al. Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase. J. Virol. 88, 2584\u20132599. https:\/\/doi.org\/10.1128\/jvi.02575-13 (2013).","journal-title":"J. Virol."},{"key":"66505_CR15","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1128\/jvi.07137-11","volume":"86","author":"SA Jones","year":"2012","unstructured":"Jones, S. A., Boregowda, R., Spratt, T. E. & Hu, J. In vitro epsilon RNA-dependent protein priming activity of human hepatitis B virus polymerase. J. Virol. 86, 5134\u20135150. https:\/\/doi.org\/10.1128\/jvi.07137-11 (2012).","journal-title":"J. Virol."},{"key":"66505_CR16","doi-asserted-by":"publisher","first-page":"11447","DOI":"10.1128\/jvi.74.24.11447-11455.2000","volume":"74","author":"J Hu","year":"2000","unstructured":"Hu, J. & Anselmo, D. In vitro reconstitution of a functional duck hepatitis B virus reverse transcriptase: Posttranslational activation by Hsp90. J. Virol. 74, 11447\u201311455. https:\/\/doi.org\/10.1128\/jvi.74.24.11447-11455.2000 (2000).","journal-title":"J. Virol."},{"key":"66505_CR17","doi-asserted-by":"publisher","first-page":"105249","DOI":"10.1016\/j.antiviral.2022.105249","volume":"198","author":"Y Yao","year":"2022","unstructured":"Yao, Y. et al. RNA-binding motif protein 38 (RBM38) mediates HBV pgRNA packaging into the nucleocapsid. Antiviral Res. 198, 105249. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105249 (2022).","journal-title":"Antiviral Res."},{"key":"66505_CR18","doi-asserted-by":"publisher","first-page":"8705","DOI":"10.1128\/jvi.01229-16","volume":"90","author":"N Unchwaniwala","year":"2016","unstructured":"Unchwaniwala, N., Sherer, N. M. & Loeb, D. D. Hepatitis B virus polymerase localizes to the mitochondria, and its terminal protein domain contains the mitochondrial targeting signal. J. Virol. 90, 8705\u20138719. https:\/\/doi.org\/10.1128\/jvi.01229-16 (2016).","journal-title":"J. Virol."},{"key":"66505_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1128\/mmbr.64.1.51-68.2000","volume":"64","author":"C Seeger","year":"2000","unstructured":"Seeger, C. & Mason, W. S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64, 51\u201368. https:\/\/doi.org\/10.1128\/mmbr.64.1.51-68.2000 (2000).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"66505_CR20","doi-asserted-by":"publisher","first-page":"e1010739","DOI":"10.1371\/journal.ppat.1010739","volume":"18","author":"X Hong","year":"2022","unstructured":"Hong, X., Menne, S. & Hu, J. Constrained evolution of overlapping genes in viral host adaptation: Acquisition of glycosylation motifs in hepadnaviral precore\/core genes. PLoS Pathog. 18, e1010739. https:\/\/doi.org\/10.1371\/journal.ppat.1010739 (2022).","journal-title":"PLoS Pathog."},{"key":"66505_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/bf00175817","volume":"41","author":"Z Yang","year":"1995","unstructured":"Yang, Z., Lauder, I. J. & Lin, H. J. Constrained evolution with respect to gene overlap of hepatitis B virus. J. Mol. Evol. 41, 587\u2013596. https:\/\/doi.org\/10.1007\/bf00175817 (1995).","journal-title":"J. Mol. Evol."},{"key":"66505_CR22","doi-asserted-by":"publisher","first-page":"e0240120","DOI":"10.1128\/jvi.02401-20","volume":"95","author":"S Nakajima","year":"2021","unstructured":"Nakajima, S. et al. Biochemical and structural properties of entecavir-resistant hepatitis B virus polymerase with L180M\/M204V mutations. J. Virol. 95, e0240120. https:\/\/doi.org\/10.1128\/jvi.02401-20 (2021).","journal-title":"J. Virol."},{"key":"66505_CR23","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1128\/jvi.02395-06","volume":"81","author":"DR Langley","year":"2007","unstructured":"Langley, D. R. et al. Inhibition of hepatitis B virus polymerase by entecavir. J. Virol. 81, 3992\u20134001. https:\/\/doi.org\/10.1128\/jvi.02395-06 (2007).","journal-title":"J. Virol."},{"key":"66505_CR24","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1128\/jvi.75.10.4771-4779.2001","volume":"75","author":"K Das","year":"2001","unstructured":"Das, K. et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75, 4771\u20134779. https:\/\/doi.org\/10.1128\/jvi.75.10.4771-4779.2001 (2001).","journal-title":"J. Virol."},{"key":"66505_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589. https:\/\/doi.org\/10.1038\/s41586-021-03819-2 (2021).","journal-title":"Nature"},{"key":"66505_CR26","doi-asserted-by":"publisher","first-page":"e4421","DOI":"10.1002\/pro.4421","volume":"31","author":"R Tajwar","year":"2022","unstructured":"Tajwar, R., Bradley, D. P., Ponzar, N. L. & Tavis, J. E. Predicted structure of the hepatitis B virus polymerase reveals an ancient conserved protein fold. Protein Sci. 31, e4421. https:\/\/doi.org\/10.1002\/pro.4421 (2022).","journal-title":"Protein Sci."},{"key":"66505_CR27","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/s41598-018-19602-9","volume":"8","author":"Y Yasutake","year":"2018","unstructured":"Yasutake, Y. et al. HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: Structural insights into HBV-RT inhibition by entecavir. Sci. Rep. 8, 1624. https:\/\/doi.org\/10.1038\/s41598-018-19602-9 (2018).","journal-title":"Sci. Rep."},{"key":"66505_CR28","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1038\/s41598-020-59775-w","volume":"10","author":"Y Yasutake","year":"2020","unstructured":"Yasutake, Y. et al. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine. Sci. Rep. 10, 3021. https:\/\/doi.org\/10.1038\/s41598-020-59775-w (2020).","journal-title":"Sci. Rep."},{"key":"66505_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/095632020301400603","volume":"14","author":"Y Chong","year":"2003","unstructured":"Chong, Y., Stuyver, L., Otto, M. J., Schinazi, R. F. & Chu, C. K. Mechanism of antiviral activities of 3\u02b9-substituted L-nucleosides against 3TC-resistant HBV polymerase: A molecular modelling approach. Antivir. Chem. Chemother. 14, 309\u2013319. https:\/\/doi.org\/10.1177\/095632020301400603 (2003).","journal-title":"Antivir. Chem. Chemother."},{"key":"66505_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1006\/jmbi.2000.3823","volume":"300","author":"HQ Gao","year":"2000","unstructured":"Gao, H. Q., Boyer, P. L., Sarafianos, S. G., Arnold, E. & Hughes, S. H. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J. Mol. Biol. 300, 403\u2013418. https:\/\/doi.org\/10.1006\/jmbi.2000.3823 (2000).","journal-title":"J. Mol. Biol."},{"key":"66505_CR31","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.bbrc.2019.01.026","volume":"509","author":"Y Yasutake","year":"2019","unstructured":"Yasutake, Y. et al. Active-site deformation in the structure of HIV-1 RT with HBV-associated septuple amino acid substitutions rationalizes the differential susceptibility of HIV-1 and HBV against 4\u02b9-modified nucleoside RT inhibitors. Biochem. Biophys. Res. Commun. 509, 943\u2013948. https:\/\/doi.org\/10.1016\/j.bbrc.2019.01.026 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"66505_CR32","doi-asserted-by":"publisher","first-page":"9274","DOI":"10.1073\/pnas.1605223113","volume":"113","author":"ZL Salie","year":"2016","unstructured":"Salie, Z. L. et al. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4\u2019-ethynyl-2-fluoro-2\u2019-deoxyadenosine (EFdA). Proc. Natl. Acad. Sci. U.S.A. 113, 9274\u20139279. https:\/\/doi.org\/10.1073\/pnas.1605223113 (2016).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"66505_CR33","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1093\/emboj\/cdf637","volume":"21","author":"SG Sarafianos","year":"2002","unstructured":"Sarafianos, S. G. et al. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21, 6614\u20136624. https:\/\/doi.org\/10.1093\/emboj\/cdf637 (2002).","journal-title":"EMBO J."},{"key":"66505_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nsmb760","volume":"11","author":"S Tuske","year":"2004","unstructured":"Tuske, S. et al. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat. Struct. Mol. Biol. 11, 469\u2013474. https:\/\/doi.org\/10.1038\/nsmb760 (2004).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"66505_CR35","doi-asserted-by":"publisher","first-page":"7308","DOI":"10.1073\/pnas.1814170116","volume":"116","author":"K Das","year":"2019","unstructured":"Das, K., Martinez, S. E., DeStefano, J. J. & Arnold, E. Structure of HIV-1 RT\/dsRNA initiation complex prior to nucleotide incorporation. Proc. Natl. Acad. Sci. U.S.A. 116, 7308\u20137313. https:\/\/doi.org\/10.1073\/pnas.1814170116 (2019).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"66505_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s42003-019-0706-x","volume":"2","author":"M Hung","year":"2019","unstructured":"Hung, M. et al. Elucidating molecular interactions of L-nucleotides with HIV-1 reverse transcriptase and mechanism of M184V-caused drug resistance. Commun. Biol. 2, 469\u2013469. https:\/\/doi.org\/10.1038\/s42003-019-0706-x (2019).","journal-title":"Commun. Biol."},{"key":"66505_CR37","doi-asserted-by":"publisher","first-page":"e00224","DOI":"10.1128\/aac.00224","volume":"61","author":"K Das","year":"2017","unstructured":"Das, K., Martinez, S. E. & Arnold, E. Structural insights into HIV reverse transcriptase mutations Q151M and Q151M complex that confer multinucleoside drug resistance. Antimicrob. Agents Chemother. 61, e00224. https:\/\/doi.org\/10.1128\/aac.00224 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"66505_CR38","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/hep.27962","volume":"62","author":"Y Takamatsu","year":"2015","unstructured":"Takamatsu, Y. et al. 4\u2032-Modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus. Hepatology 62, 1024\u20131036. https:\/\/doi.org\/10.1002\/hep.27962 (2015).","journal-title":"Hepatology"},{"key":"66505_CR39","doi-asserted-by":"publisher","first-page":"15999","DOI":"10.1039\/d3ra01750h","volume":"13","author":"H Kumamoto","year":"2023","unstructured":"Kumamoto, H. et al. Synthesis of novel entecavir analogues having 4\u02b9-cyano-6\u02b9\u02b9-fluoromethylenecyclopentene skeletons as an aglycone moiety as highly potent and long-acting anti-hepatitis B virus agent. RSC Adv. 13, 15999\u201316011. https:\/\/doi.org\/10.1039\/d3ra01750h (2023).","journal-title":"RSC Adv."},{"key":"66505_CR40","doi-asserted-by":"publisher","first-page":"e50859","DOI":"10.1371\/journal.pone.0050859","volume":"7","author":"J Vermeire","year":"2012","unstructured":"Vermeire, J. et al. Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors. PLoS ONE 7, e50859. https:\/\/doi.org\/10.1371\/journal.pone.0050859 (2012).","journal-title":"PLoS ONE"},{"key":"66505_CR41","doi-asserted-by":"publisher","first-page":"35681","DOI":"10.1074\/jbc.m109.036616","volume":"284","author":"E Michailidis","year":"2008","unstructured":"Michailidis, E. et al. Mechanism of inhibition of HIV-1 reverse transcriptase by 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J. Biol. Chem. 284, 35681\u201335691. https:\/\/doi.org\/10.1074\/jbc.m109.036616 (2008).","journal-title":"J. Biol. Chem."},{"key":"66505_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/pro.2776","volume":"25","author":"MT Miller","year":"2015","unstructured":"Miller, M. T., Tuske, S., Das, K., DeStefano, J. J. & Arnold, E. Structure of HIV-1 reverse transcriptase bound to a novel 38-mer hairpin template-primer DNA aptamer. Protein Sci. 25, 46. https:\/\/doi.org\/10.1002\/pro.2776 (2015).","journal-title":"Protein Sci."},{"key":"66505_CR43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. Sect. D 66, 125\u2013132. https:\/\/doi.org\/10.1107\/S0907444909047337 (2010).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"66505_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1107\/s0907444905036693","volume":"62","author":"P Evans","year":"2006","unstructured":"Evans, P. Scaling and assessment of data quality. Acta Crystallogr. Sect. D 62, 72\u201382. https:\/\/doi.org\/10.1107\/s0907444905036693 (2006).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"66505_CR45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1107\/s0907444911001314","volume":"67","author":"GN Murshudov","year":"2011","unstructured":"Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. Sect. D 67, 355\u2013367. https:\/\/doi.org\/10.1107\/s0907444911001314 (2011).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"66505_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1107\/s0907444910045749","volume":"67","author":"MD Winn","year":"2011","unstructured":"Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. Sect. D 67, 235\u2013242. https:\/\/doi.org\/10.1107\/s0907444910045749 (2011).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"66505_CR47","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1107\/s0907444904016427","volume":"60","author":"E Blanc","year":"2004","unstructured":"Blanc, E. et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr. Sect. D 60, 2210\u20132221. https:\/\/doi.org\/10.1107\/s0907444904016427 (2004).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"66505_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/s0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. Phenix: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D 66, 213\u2013221. https:\/\/doi.org\/10.1107\/s0907444909052925 (2010).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"66505_CR49","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/s0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D 66, 486\u2013501. https:\/\/doi.org\/10.1107\/s0907444910007493 (2010).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"66505_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/s0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D 66, 12\u201321. https:\/\/doi.org\/10.1107\/s0907444909042073 (2010).","journal-title":"Acta Crystallogr. Sect. D"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66505-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66505-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66505-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T17:10:10Z","timestamp":1720458610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66505-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["66505"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-66505-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.K. and H.M. are listed as coinventors in a patent regarding <i>E<\/i>-CFCP. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15742"}}